Skip to main content

Advertisement

SpringerLink
Log in

The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy

  • Original Article
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

The effect of continuing or discontinuing chronic angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy prior to coronary angiography on the incidence of contrast-induced nephropathy (CIN) is not clear. We undertook a randomized trial to evaluate the effect of withdrawing ACEIs or ARBs 24 h prior to coronary angiography on the incidence of CIN associated with coronary angiography.

Methods

A total of 220 patients with chronic kidney disease (CKD) stages 3–4 (glomerular filtration rate 15–60 ml/min/1.73 m2) on ACEI or ARB therapy were randomized before angiography to either ACEI/ARB continuation group or discontinuation group. A third group of patients with CKD stages 3–4 but not on angiotensin blockade therapy were also followed. The primary outcome measure was the incidence of CIN defined by a rise in serum creatinine by 25% or 0.5 mg/dl (44 μmol/l) from baseline.

Results

There was no statistically significant difference in the incidence of CIN between the three groups (P = 0.66). The incidences were 6.2%, 3.7%, and 6.3% for the continuation, discontinuation, and angiotensin blockade naïve group, respectively. There was also no significant difference found between the groups in mean serum creatinine and glomerular filtration rate values at baseline and post contrast administration.

Conclusion

Withholding ACEIs and ARBs 24 h before coronary angiography does not appear to influence the incidence of CIN in stable patients with CKD stages 3–4.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264

    Article  PubMed  Google Scholar 

  2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW (1997) Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 103:368–375

    Article  PubMed  CAS  Google Scholar 

  3. Barrett BJ, Parfrey PS (2006) Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 354:379–386

    Article  PubMed  CAS  Google Scholar 

  4. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM et al (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36:1542–1548

    Article  PubMed  CAS  Google Scholar 

  5. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN et al (2005) Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95:13–19

    Article  PubMed  Google Scholar 

  6. Weinstein JM, Heyman S, Brezis M (1992) Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 62:413–415

    PubMed  CAS  Google Scholar 

  7. Solomon R, Werner C, Mann D, D’Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416–1420

    Article  PubMed  CAS  Google Scholar 

  8. Dzgoeva FU, Milovanov IuS, Kutyrina IM (1995) Acute kidney failure related to the use of x-ray contrast agents and indomethacin: the risk factors and mechanisms of its development. Ter Arkh 67(5):36–39

    PubMed  CAS  Google Scholar 

  9. Solomon R, Deray G (2006) Consensus panel for CIN. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 69:S51–S53

    Article  Google Scholar 

  10. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK (1999) Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 51:521–526

    PubMed  CAS  Google Scholar 

  11. Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685–693

    Article  PubMed  CAS  Google Scholar 

  12. Palmer BF (2002) Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347:1256–1261

    Article  PubMed  Google Scholar 

  13. Mahajan S, Tiwari S, Bhowmik D, Agarwal SK, Tiwari SC, Dash SC (2006) Factors affecting the outcome of acute renal failure among the elderly population in India: a hospital based study. Int Urol Nephrol 38:391–396

    Article  PubMed  Google Scholar 

  14. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E (2006) Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 104:c20–c27

    Article  PubMed  CAS  Google Scholar 

  15. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL (2003) The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 3(2):104–106

    Google Scholar 

  16. Maeder M, Klein M, Fehr T, Rickli H (2004) Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44:1763–1771

    Article  PubMed  Google Scholar 

  17. Gami AS, Garovic VD (2004) Contrast nephropathy after coronary angiography. Mayo Clin Proc 79:211–219

    Article  PubMed  Google Scholar 

  18. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266

    Google Scholar 

  19. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31

    Article  PubMed  Google Scholar 

  20. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M et al (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:1393–1399

    PubMed  Google Scholar 

  21. Solomon R (2005) The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 68:2256–2263

    Article  PubMed  CAS  Google Scholar 

  22. Barrett BJ, Carlisle EJ (1993) Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188:171–178

    PubMed  CAS  Google Scholar 

  23. Guitterez NV, Diaz A, Timmis GC, O’Neill WW, Stevens MA, Sandberg KR, McCullough PA (2002) Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 15:349–354

    Article  PubMed  Google Scholar 

  24. Given BD, Taylor T, Hollenberg NK, Williams GH (1984) Duration of action and short-term hormonal responses to enalapril (MK-421) in normal subjects. J Cardiovasc Pharmacol 6:436–441

    Article  PubMed  CAS  Google Scholar 

  25. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ et al (1981) Three new long-active converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin inhibition. J Clin Pharmacol Ther 29:665–670

    PubMed  CAS  Google Scholar 

  26. Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A. (2001) Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. J Cardiovasc Pharmacol 37(4):449–460

    Article  PubMed  CAS  Google Scholar 

  27. Belz GG, Butzer R, Kober S, Mutschler E (2002) Pharmacodynamic studies on the angiotensin II type I antagonists irbesartan and candesartan based on angiotensin II dose response in humans. J Cardiovasc Pharmacol 39(4):561–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Lenox Hill Hospital, 130 E 77th Street, 5th Floor, New York, NY, 10021, USA

    Jordan L. Rosenstock, Robert Bruno, Jin K. Kim, Maria V. DeVita & Michael F. Michelis

  2. Division of Cardiology, Lenox Hill Hospital, New York, NY, 10021, USA

    Lev Lubarsky

  3. Department of Internal Medicine, Lenox Hill Hospital, New York, NY, 10021, USA

    Robert Schaller

  4. Department of Research, Lenox Hill Hospital, New York, NY, 10021, USA

    Georgia Panagopoulos

Authors
  1. Jordan L. Rosenstock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lev Lubarsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Schaller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georgia Panagopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria V. DeVita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael F. Michelis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jordan L. Rosenstock.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenstock, J.L., Bruno, R., Kim, J.K. et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 40, 749–755 (2008). https://doi.org/10.1007/s11255-008-9368-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-008-9368-1

Keywords

Search

Navigation